Approval is based on Phase III INAVO120 results, showing the ItovebiTM (inavolisib)-based regimen more than doubled progression-free survival compared with ...
This year’s Q4 report newly reflects tocilizumab’s market share and Wholesale Acquisition Cost (WAC) trend analysis after biosimilars launched in Q2 Biosimilar Deep Dive section presents US biosimilar ...
Proprietary cell-free platform enables the design of next-generation ADCs intended to broaden addressable patient populations ...